Almond, S. & O'Donnell, O. (2000) Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine, risperidone and haloperidol. Pharmacoeconomics, 17, 383–389.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) . Washington, DC: APA.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) . Washington, DC: APA.
Beecham, J. K. & Knapp, M. R. J. (1992) Costing psychiatric interventions. In Measuring Mental Health Needs (eds Thornicroft, G., Brewin, C. & Wing, J. K.), pp. 163–183. London: Gaskell.
Beecham, J. K. & Knapp, M. R. J. (2001) Costing psychiatric interventions. In Measuring Mental Health Needs (ed. Thornicroft, G.) (2nd edn), pp. 200–224. London: Gaskell.
Birchwood, M., Smith, J., Macmillan, F., et al (1989) Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers: a preliminary investigation. Psychological Medicine, 19, 649–656.
Davies, L. M. & Drummond, M. F. (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophreniain the United Kingdom. British Journal of Psychiatry, 162, 38–42.
Dunn, G., Mirandola, M., Amaddeo, F., et al (2003) Describing, explaining or predicting mental health care costs: a guide to regression models: methodological review. British Journal of Psychiatry, 183, 398–404.
Guy, W. (1976) Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology, . Rockville, MD: National Institute of Mental Health.
Hamilton, S. H., Revicki, D. A., Edgell, E. T., et al (1999) Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from arandomised trial. Pharmacoeconomics, 15, 469–480.
Herz, M. I., Lamberti, S., Mintx, J., et al (2000) A programme for relapse prevention in schizophrenia: a controlled study. Archives of General Psychiatry, 57, 277–283.
Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.
Kemp, R., Hayward, P., Applewhaite, G., et al (1996) Compliance therapy in psychotic patients: randomised controlled trial. BMJ, 312, 345–349.
Kind, P. (1996) The EuroQoL instrument: an index of health-related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials (ed. Spilker, B.). Philadelphia: Lippincott–Raven.
Knapp, M. R. J., Simon, J., Almond, S., et al (2003) Costs of schizophrenia. In WPA Series in Evidence and Experience in Psychiatry: Schizophrenia (eds Maj, M. & Sartorius, N.), pp. 413–460. New York: Wiley.
Knapp, M. R. J., Mangalore, R. & Simon, J. (2004) The global costs of schizophrenia. Schizophrenia Bulletin, .
Lader, M. (1995) What is relapse in schizophrenia?
International Clinical Psychopharmacology, 9 (suppl. 5), 5–9.
Lehman, A. F. (1996) Quality of life among persons with severe and persistent mental disorders. In Mental Health Outcome Measures (eds Thornicroft, G. & Tansella, M.), pp. 75–92. London: Springer.
National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. . London: NICE.
Netten, A., Dennett, J. & Knight, J. (1999) Unit Costs of Health and Social Care 1999. Canterbury: PSSRU, University of Kent.
Robinson, D., Woerner, M. G., Ma, J., et al (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241–247.
Weiden, P J. & Olfson, M. (1995) Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21, 419–429.
Xiong, W., Phillips, M. R., Hu, X., et al (1994) Family-based intervention for schizophrenic patients in China: a randomised controlled trial. British Journal of Psychiatry, 165, 239–247.